← Back to Search

Monoclonal Antibodies

IPH6501 for Non-Hodgkin's Lymphoma

Phase 1 & 2

Recruiting

Research Sponsored by Innate Pharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: Diffuse Large B Cell Lymphoma (DLBCL); high grade; thymic; Follicular Lymphoma (FL); Mantle cell lymphoma (MCL); Marginal zone lymphoma (MZL)

Relapsed, progressive and/or refractory disease without established alternative therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from time of informed consent through treatment period and including the follow-up: up to 22 months

Awards & highlights

Study Summary

This trial evaluates a new drug's safety and how much of it is needed to treat B-Cell non-Hodgkin lymphoma.

Who is the study for?

This trial is for patients with advanced B-cell non-Hodgkin's lymphoma who have tried at least two treatments, including anti-CD20 antibody therapy. They should be in a condition to perform daily activities (ECOG ≤ 2) and have good organ function. A recent or historical biopsy is required. Those with other cancers within the last 2 years, recent cancer therapies, CNS issues, HIV/hepatitis infections, major surgery within the past month or pregnancy are excluded.Check my eligibility

What is being tested?

The study tests IPH6501 on people with relapsed/refractory B-cell non-Hodgkin lymphoma to assess safety and find the best dose for Phase 2 trials. It's an international study where everyone gets IPH6501; there are no comparison groups.See study design

What are the potential side effects?

While specific side effects of IPH6501 aren't listed here, similar drugs can cause immune reactions, fatigue, infusion-related symptoms like fever or chills, blood count changes increasing infection risk and potential liver or kidney issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a type of non-Hodgkin's lymphoma that tests positive for CD20.

Select...

My condition is worsening and there are no other treatment options for me.

Select...

I have had at least 2 treatments for my condition, including one with an anti-CD20 drug.

Select...

I can take care of myself but might not be able to do heavy physical work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from time of informed consent through treatment period and including the follow-up: up to 22 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from time of informed consent through treatment period and including the follow-up: up to 22 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of informed consent through treatment period and including the follow-up: up to 22 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and tolerability

Secondary outcome measures

Area Under the Plasma Concentration (AUC)

Duration Of Response (DoR)

Incidence of antidrug antibodies (ADA) against IPH6501

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: IPH6501 monotherapyExperimental Treatment1 Intervention

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Innate PharmaLead Sponsor

27 Previous Clinical Trials

2,857 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently being recruited for participation in this experiment?

"The data posted on clinicaltrials.gov denotes that the study, which was first uploaded on October 7th 2023 and last amended on December 10th of the same year, is no longer open to candidates. However, a trove of 1776 other trials are presently recruiting potential patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

2024. "Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06088654.